Analysis-China’s Biotech Sector Comes of Age With Big Licensing Deals, Global Ambitions

If investors in China’s biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd struck last month with Seattle-based Seagen Inc fits the bill …
( read original story …)

---